Recurrent Mantle Cell Lymphoma Clinical Trials

10 recruiting

Frequently Asked Questions

Common questions about Recurrent Mantle Cell Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 2

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
National Cancer Institute (NCI)20 enrolled1 locationNCT07003295
Recruiting
Phase 1

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

Diffuse Large B Cell LymphomaMantle Cell LymphomaB-cell Non Hodgkin Lymphoma+5 more
City of Hope Medical Center15 enrolled1 locationNCT05432635
Recruiting
Phase 1

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Recurrent Chronic Lymphocytic LeukemiaRecurrent Follicular LymphomaRecurrent Small Lymphocytic Lymphoma+12 more
Mayo Clinic27 enrolled1 locationNCT06191887
Recruiting
Phase 2

Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center80 enrolled1 locationNCT04054167
Recruiting
Phase 1

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
City of Hope Medical Center10 enrolled1 locationNCT06675123
Recruiting
Phase 2

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
City of Hope Medical Center36 enrolled1 locationNCT04484012
Recruiting
Phase 2

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Chronic Lymphocytic LeukemiaMantle Cell LymphomaRecurrent Chronic Lymphocytic Leukemia+6 more
Fred Hutchinson Cancer Center20 enrolled1 locationNCT06839053
Recruiting
Phase 2

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Recurrent Follicular LymphomaRefractory Follicular LymphomaRecurrent B-Cell Non-Hodgkin Lymphoma+8 more
University of Washington40 enrolled1 locationNCT05453396
Recruiting
Phase 1

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Diffuse Large B-Cell Lymphoma+16 more
City of Hope Medical Center37 enrolled1 locationNCT06859008
Recruiting
Phase 2

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
Academic and Community Cancer Research United100 enrolled2 locationsNCT05910801